Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL)
| Autor: | Becky Habecker, Brian T. Hill, Matt Kalaycio, Tammy Kindwall-Keller, Paolo Caimi |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Bendamustine Chemotherapy medicine.medical_specialty Lymphocytic leukaemia medicine.drug_class business.industry medicine.medical_treatment Hematology Antibodies Monoclonal Humanized Monoclonal antibody Leukemia Lymphocytic Chronic B-Cell Treatment Outcome Fludarabine refractory Internal medicine Antineoplastic Combined Chemotherapy Protocols Nitrogen Mustard Compounds medicine Bendamustine Hydrochloride Humans Alemtuzumab business Vidarabine medicine.drug |
| Zdroj: | British Journal of Haematology. 164:297-299 |
| ISSN: | 0007-1048 |
| DOI: | 10.1111/bjh.12604 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text